| 词条 | Telik |
| 释义 |
| name = Telik Inc | type = | traded_as = | industry = Healthcare, Drug Manufacturers - Other | products = | foundation = 1988 | location_city = Palo Alto, California | location_country = United States | key_people = Michael M. Wick M.D. ({{small| Chairman, Chief Executive Officer, and President}}) Wendy K. Wee Gail L. Brown M.D. | num_employees = 17 (Dec 31, 2012) | homepage = }}Telik, Inc. was set up in 1988 and was reverse merged into privately held MabVax in May 2014.[1] The major drug of the company was TELINTRA, an investigational agent that was in development for the treatment of myelodysplastic syndrome (MDS) and idiopathic chronic neutropenia.[2] ControversiesIn 2007, a class action was filed against Telik, Inc., alleging that they made false and misleading statements about the Company’s business and prospects during the Class Period.[3] References1. ^{{cite web |url=https://www.thestreet.com/story/12705673/1/telik-biotech-pariah-finally-died.html|title=Reverse merger}} 2. ^{{cite web |url= https://finance.yahoo.com/q/pr?s=TELK+Profile|title= Business Summary}} 3. ^{{cite web |url=http://www.businesswire.com/news/home/20070606006160/en/Lerach-Coughlin-Stoia-Geller-Rudman-Robbins-LLP#.Uv72jXGeig4|title=Lerach Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit Against Telik, Inc.}} 2 : Companies established in 1988|2014 mergers and acquisitions |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。